{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:26:09Z","timestamp":1779877569970,"version":"3.53.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0073"],"award-info":[{"award-number":["W81XWH-21-1-0073"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","award":["I01BX004423"],"award-info":[{"award-number":["I01BX004423"]}],"id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016953","name":"Comprehensive Cancer Center, University of California, Davis","doi-asserted-by":"publisher","award":["P30CA093373"],"award-info":[{"award-number":["P30CA093373"]}],"id":[{"id":"10.13039\/100016953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoadjuvant therapy (NAT) has been studied in clinically localized prostate cancer (PCa) to improve the outcomes from radical prostatectomy (RP) by \u2018debulking\u2019 of high-risk PCa; however, using androgen deprivation therapy (ADT) at this point risks castration resistant PCa (CRPC) clonal proliferation. Our goal is to identify alternative NAT that reduce hormone sensitive PCa (HSPC) without affecting androgen receptor (AR) transcriptional activity. PCa is associated with increased expression and activation of the epidermal growth factor receptor (EGFR) family, including HER2 and ErbB3. The FDA-approved HER2 inhibitor lapatinib has been tested in PCa but was ineffective due to continued activation of ErbB3. We now demonstrate that this is due to ErbB3 being localized to the nucleus in HSPC and thus protected from lapatinib which affect membrane localized HER2\/ErbB3 dimers. Here, we show that the well-established, well-tolerated potassium-sparing diuretic amiloride hydrochloride dose dependently prevented ErbB3 nuclear localization via formation of plasma membrane localized HER2\/ErbB3 dimers. This in turn allowed lapatinib inactivation of these dimers via inhibition of its target HER2, which dephosphorylated ERK1\/2 and inhibited survival. Amiloride combined with lapatinib significantly increased apoptosis at relatively low doses of both drugs but did not affect AR transcriptional activity. Thus, our data indicate that a combination of amiloride and lapatinib could target HSPC tumors without problems associated with using ADT as NAT in HSPC.<\/jats:p>","DOI":"10.1007\/s00018-024-05540-5","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T21:45:33Z","timestamp":1735249533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amiloride sensitizes prostate cancer cells to the reversible tyrosine kinase inhibitor lapatinib by modulating Erbb3 subcellular localization"],"prefix":"10.1007","volume":"82","author":[{"given":"Maitreyee K.","family":"Jathal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mudryj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Dall\u2019Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-2936","authenticated-orcid":false,"given":"Paramita M.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"issue":"3","key":"5540_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.juro.2012.04.109","volume":"188","author":"JB Eifler","year":"2012","unstructured":"Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M (2012) Causes of death after radical prostatectomy at a large tertiary center. J Urol 188(3):798\u2013801","journal-title":"J Urol"},{"issue":"2","key":"5540_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ (2024) Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis 27(2):192\u2013201","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"5540_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12894-019-0470-8","volume":"19","author":"Y Koskas","year":"2019","unstructured":"Koskas Y, Lannes F, Branger N, Giusiano S, Guibert N, Pignot G et al (2019) Extent of positive surgical margins following radical prostatectomy: impact on biochemical recurrence with long-term follow-up. BMC Urol 19(1):37","journal-title":"BMC Urol"},{"issue":"26","key":"5540_CR4","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.20.00315","volume":"38","author":"JA Eastham","year":"2020","unstructured":"Eastham JA, Heller G, Halabi S, Monk JP 3rd, Beltran H, Gleave M et al (2020) Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without Neoadjuvant Chemohormonal Therapy in Localized, high-risk prostate Cancer. J Clin Oncol 38(26):3042\u20133050","journal-title":"J Clin Oncol"},{"issue":"1","key":"5540_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/PPO.0000000000000424","volume":"26","author":"ST Ryan","year":"2020","unstructured":"Ryan ST, Patel DN, Parsons JK, McKay RR (2020) Neoadjuvant approaches prior to radical prostatectomy. Cancer J 26(1):2\u201312","journal-title":"Cancer J"},{"issue":"12","key":"5540_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","volume":"18","author":"G Devos","year":"2021","unstructured":"Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L et al (2021) Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Reviews Urol 18(12):739\u2013762","journal-title":"Nat Reviews Urol"},{"key":"5540_CR7","doi-asserted-by":"crossref","unstructured":"Messner EA, Steele TM, Tsamouri MM, Hejazi N, Gao AC, Mudryj M et al (2020) The androgen receptor in prostate Cancer: Effect of structure, ligands and spliced variants on Therapy. Biomedicines. 8(10)","DOI":"10.3390\/biomedicines8100422"},{"key":"5540_CR8","doi-asserted-by":"crossref","unstructured":"Cartes R, Karim MU, Tisseverasinghe S, Tolba M, Bahoric B, Anidjar M et al (2023) Neoadjuvant versus concurrent androgen deprivation therapy in localized prostate Cancer treated with Radiotherapy: a systematic review of the literature. Cancers (Basel). 15(13)","DOI":"10.3390\/cancers15133363"},{"key":"5540_CR9","doi-asserted-by":"crossref","unstructured":"Pechlivanis M, Campbell BK, Hovens CM, Corcoran NM (2021) Biomarkers of response to neoadjuvant androgen deprivation in localised prostate Cancer. Cancers (Basel).;14(1)","DOI":"10.3390\/cancers14010166"},{"issue":"6","key":"5540_CR10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.urology.2013.06.062","volume":"82","author":"HA Gay","year":"2013","unstructured":"Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA et al (2013) Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality\/hormonal and sexual quality of life: results of a multicenter prospective study. Urology 82(6):1363\u20131368","journal-title":"Urology"},{"issue":"13","key":"5540_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s40265-013-0107-2","volume":"73","author":"RR McKay","year":"2013","unstructured":"McKay RR, Choueiri TK, Taplin ME (2013) Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs 73(13):1417\u20131430","journal-title":"Drugs"},{"key":"5540_CR12","doi-asserted-by":"crossref","unstructured":"Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG et al (2010) Nrdp1-Mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate Cancer cells. Cancer Res","DOI":"10.1158\/0008-5472.CAN-09-4440"},{"issue":"22","key":"5540_CR13","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/sj.onc.1201447","volume":"15","author":"AW Grasso","year":"1997","unstructured":"Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ (1997) ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 15(22):2705\u20132716","journal-title":"Oncogene"},{"issue":"19","key":"5540_CR14","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1158\/1078-0432.CCR-11-1548","volume":"17","author":"L Chen","year":"2011","unstructured":"Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E et al (2011) Dual EGFR\/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 17(19):6218\u20136228","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5540_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2174\/187152211795495643","volume":"11","author":"MK Jathal","year":"2011","unstructured":"Jathal MK, Chen L, Mudryj M, Ghosh PM (2011) Targeting ErbB3: the New RTK(id) on the prostate Cancer Block. Immunol Endocr Metab Agents Med Chem 11(2):131\u2013149","journal-title":"Immunol Endocr Metab Agents Med Chem"},{"issue":"4","key":"5540_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1517\/14728214.2014.969239","volume":"19","author":"MA Ojemuyiwa","year":"2014","unstructured":"Ojemuyiwa MA, Madan RA, Dahut WL (2014) Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs 19(4):459\u2013470","journal-title":"Expert Opin Emerg Drugs"},{"key":"5540_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2407-7-142","volume":"7","author":"M Gross","year":"2007","unstructured":"Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K et al (2007) A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7:142","journal-title":"BMC Cancer"},{"issue":"3","key":"5540_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.urology.2009.05.016","volume":"74","author":"C Nabhan","year":"2009","unstructured":"Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D et al (2009) Erlotinib has moderate single-agent activity in chemotherapy-na\u00efve castration-resistant prostate cancer: final results of a phase II trial. Urology 74(3):665\u2013671","journal-title":"Urology"},{"issue":"21","key":"5540_CR19","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1158\/1078-0432.CCR-12-2219","volume":"18","author":"R Cathomas","year":"2012","unstructured":"Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC et al (2012) Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08\/07). Clin Cancer Res 18(21):6049\u20136057","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5540_CR20","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/sj.bjc.6604043","volume":"97","author":"G Attard","year":"2007","unstructured":"Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J et al (2007) A phase ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 97(10):1338\u20131343","journal-title":"Br J Cancer"},{"issue":"1","key":"5540_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.urolonc.2010.09.018","volume":"31","author":"YE Whang","year":"2013","unstructured":"Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS et al (2013) A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol 31(1):82\u201386","journal-title":"Urol Oncol"},{"issue":"26","key":"5540_CR22","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733\u20132743","journal-title":"N Engl J Med"},{"issue":"3","key":"5540_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41416-019-0496-4","volume":"121","author":"MK Jathal","year":"2019","unstructured":"Jathal MK, Steele TM, Siddiqui S, Mooso BA, D\u2019Abronzo LS, Drake CM et al (2019) Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. Br J Cancer 121(3):237\u2013248","journal-title":"Br J Cancer"},{"key":"5540_CR24","doi-asserted-by":"crossref","unstructured":"Jathal MK, Siddiqui S, Vasilatis DM, Durbin Johnson BP, Drake C, Mooso BA et al (2023) Androgen receptor transcriptional activity is required for heregulin-1\u03b2-mediated nuclear localization of the HER3\/ErbB3 receptor tyrosine kinase. J Biol Chem.:104973","DOI":"10.1016\/j.jbc.2023.104973"},{"issue":"9","key":"5540_CR25","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1158\/1078-0432.CCR-05-2242","volume":"12","author":"IH Koumakpayi","year":"2006","unstructured":"Koumakpayi IH, Diallo J-S, Le Page C, Lessard L, Gleave M, B\u00e9gin LR et al (2006) Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12(9):2730\u20132737","journal-title":"Clin Cancer Res"},{"key":"5540_CR26","doi-asserted-by":"crossref","unstructured":"El Maassarani M, Barbarin A, Fromont G, Kaissi O, Lebbe M, Vannier B et al (2016) Integrated and functional genomics analysis validates the relevance of the nuclear variant erbb380kda in prostate cancer progression. PLoS ONE. 11(5)","DOI":"10.1371\/journal.pone.0155950"},{"issue":"7","key":"5540_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/1541-7786.MCR-06-0306","volume":"5","author":"C-J Cheng","year":"2007","unstructured":"Cheng C-J, Ye X-c, Vakar-Lopez F, Kim J, Tu S-M, Chen D-T et al (2007) Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675\u2013684","journal-title":"Mol Cancer Res"},{"issue":"2","key":"5540_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1464-410X.2007.06992.x","volume":"100","author":"IH Koumakpayi","year":"2007","unstructured":"Koumakpayi IH, Diallo J-S, Le Page C, Lessard L, Filali-Mouhim A, B\u00e9gin LR et al (2007) Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int 100(2):303\u2013309","journal-title":"BJU Int"},{"key":"5540_CR29","doi-asserted-by":"publisher","first-page":"570108","DOI":"10.3389\/fonc.2020.570108","volume":"10","author":"S Song","year":"2020","unstructured":"Song S, Zhang Y, Ding T, Ji N, Zhao H (2020) The dual role of macropinocytosis in cancers: promoting growth and inducing methuosis to Participate in Anticancer therapies as targets. Front Oncol 10:570108","journal-title":"Front Oncol"},{"issue":"11","key":"5540_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/mc.20766","volume":"50","author":"IH Koumakpayi","year":"2011","unstructured":"Koumakpayi IH, Le Page C, Delvoye N, Saad F, Mes-Masson AM (2011) Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Mol Carcinog 50(11):901\u2013912","journal-title":"Mol Carcinog"},{"issue":"5","key":"5540_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00424-003-1110-3","volume":"447","author":"J Orlowski","year":"2004","unstructured":"Orlowski J, Grinstein S (2004) Diversity of the mammalian sodium\/proton exchanger SLC9 gene family. Pflugers Arch 447(5):549\u2013565","journal-title":"Pflugers Arch"},{"issue":"9","key":"5540_CR32","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/ijc.26156","volume":"129","author":"H Matthews","year":"2011","unstructured":"Matthews H, Ranson M, Kelso MJ (2011) Anti-tumour\/metastasis effects of the potassium\u2010sparing diuretic amiloride: an orally active anti\u2010cancer drug waiting for its call\u2010of\u2010duty? Int J Cancer 129(9):2051\u20132061","journal-title":"Int J Cancer"},{"issue":"4","key":"5540_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1083\/jcb.200908086","volume":"188","author":"M Koivusalo","year":"2010","unstructured":"Koivusalo M, Welch C, Hayashi H, Scott CC, Kim M, Alexander T et al (2010) Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. J Cell Biol 188(4):547\u2013563","journal-title":"J Cell Biol"},{"issue":"12","key":"5540_CR34","doi-asserted-by":"publisher","first-page":"L1013","DOI":"10.1152\/ajplung.00206.2012","volume":"303","author":"HL Ji","year":"2012","unstructured":"Ji HL, Zhao RZ, Chen ZX, Shetty S, Idell S, Matalon S (2012) \u03b4 ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol 303(12):L1013\u2013L1026","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"5540_CR35","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41598-020-57601-x","volume":"10","author":"K Ando","year":"2020","unstructured":"Ando K, Wada T, Cao X (2020) Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models. Sci Rep 10(1):738","journal-title":"Sci Rep"},{"key":"5540_CR36","doi-asserted-by":"publisher","first-page":"106464","DOI":"10.1016\/j.compbiomed.2022.106464","volume":"153","author":"T Wang","year":"2023","unstructured":"Wang T, Sun J, Zhao Q (2023) Investigating cardiotoxicity related with hERG channel blockers using molecular fingerprints and graph attention mechanism. Comput Biol Med 153:106464","journal-title":"Comput Biol Med"},{"issue":"1","key":"5540_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","volume":"34","author":"GC Roush","year":"2016","unstructured":"Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA (2016) Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens 34(1):11\u201319","journal-title":"J Hypertens"},{"issue":"1","key":"5540_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0014-5793(87)80039-X","volume":"214","author":"J-D Vassalli","year":"1987","unstructured":"Vassalli J-D, Belin D (1987) Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214(1):187\u2013191","journal-title":"FEBS Lett"},{"issue":"1","key":"5540_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000218009","volume":"18","author":"RA Bhatti","year":"1997","unstructured":"Bhatti RA, Gadarowski JJ, Ray PS (1997) Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors. Tumor Biology 18(1):1\u20135","journal-title":"Tumor Biology"},{"issue":"2","key":"5540_CR40","doi-asserted-by":"publisher","first-page":"IN1","DOI":"10.1593\/neo.07822","volume":"10","author":"SA Tomlins","year":"2008","unstructured":"Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10(2):IN1\u2013IN9","journal-title":"Neoplasia"},{"issue":"4","key":"5540_CR41","first-page":"559","volume":"57","author":"J Jankun","year":"1997","unstructured":"Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R (1997) Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 57(4):559\u2013563","journal-title":"Cancer Res"},{"issue":"6","key":"5540_CR42","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ijc.2910630615","volume":"63","author":"S Rabbani","year":"1995","unstructured":"Rabbani S, Harakidas P, Davidson DJ, Henkin J, Mazar AP (1995) Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase\u2010type plasminogen activator (uPA). Int J Cancer 63(6):840\u2013845","journal-title":"Int J Cancer"},{"issue":"5","key":"5540_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2015.4","volume":"36","author":"YT Zheng","year":"2015","unstructured":"Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ et al (2015) Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K\/AKT signaling pathway. Acta Pharmacol Sin 36(5):614\u2013626","journal-title":"Acta Pharmacol Sin"},{"key":"5540_CR44","doi-asserted-by":"crossref","unstructured":"Chang W-H, Liu T-C, Yang W-K, Lee C-C, Lin Y-H, Chen T-Y et al (2011) Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. Cancer Res","DOI":"10.1158\/0008-5472.CAN-10-1037"},{"key":"5540_CR45","doi-asserted-by":"crossref","unstructured":"Jathal MK, Siddiqui S, Vasilatis DM, Johnson BPD, Drake C, Mooso BA et al (2023) Androgen receptor transcriptional activity is required for heregulin-1\u03b2-mediated nuclear localization of the HER3\/ErbB3 receptor tyrosine kinase. J Biol Chem.:104973","DOI":"10.1016\/j.jbc.2023.104973"},{"issue":"3","key":"5540_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/sj.onc.1208213","volume":"24","author":"KM Kim","year":"2005","unstructured":"Kim KM, Lee YJ (2005) Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene 24(3):355\u2013366","journal-title":"Oncogene"},{"issue":"2","key":"5540_CR47","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/jvim.15382","volume":"33","author":"AC Poon","year":"2019","unstructured":"Poon AC, Inkol JM, Luu AK, Mutsaers AJ (2019) Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells. J Vet Intern Med 33(2):800\u2013811","journal-title":"J Vet Intern Med"},{"issue":"2","key":"5540_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/ijc.21201","volume":"117","author":"RB Marques","year":"2005","unstructured":"Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T et al (2005) Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer 117(2):221\u2013229","journal-title":"Int J Cancer"},{"issue":"2","key":"5540_CR49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.eururo.2005.12.035","volume":"49","author":"RB Marques","year":"2006","unstructured":"Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J et al (2006) The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur Urol 49(2):245\u2013257","journal-title":"Eur Urol"},{"issue":"1","key":"5540_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","volume":"4","author":"J Wang","year":"2019","unstructured":"Wang J, Xu B (2019) Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Therapy 4(1):34","journal-title":"Signal Transduct Target Therapy"},{"issue":"7","key":"5540_CR51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1358\/dot.2006.42.7.985637","volume":"42","author":"SR Johnston","year":"2006","unstructured":"Johnston SR, Leary A (2006) Lapatinib: a novel EGFR\/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 42(7):441\u2013453","journal-title":"Drugs Today (Barc)"},{"issue":"9","key":"5540_CR52","first-page":"2531","volume":"5","author":"M Segovia-Mendoza","year":"2015","unstructured":"Segovia-Mendoza M, Gonz\u00e1lez-Gonz\u00e1lez ME, Barrera D, D\u00edaz L, Garc\u00eda-Becerra R (2015) Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res 5(9):2531\u20132561","journal-title":"Am J Cancer Res"},{"issue":"11","key":"5540_CR53","doi-asserted-by":"publisher","first-page":"183414","DOI":"10.1016\/j.bbamem.2020.183414","volume":"1862","author":"I Haralampiev","year":"2020","unstructured":"Haralampiev I, Alonso de Armi\u00f1o DJ, Luck M, Fischer M, Abel T, Huster D et al (2020) Interaction of the small-molecule kinase inhibitors tofacitinib and lapatinib with membranes. Biochimica et Biophysica Acta (BBA). - Biomembr 1862(11):183414","journal-title":"- Biomembr"},{"key":"5540_CR54","doi-asserted-by":"crossref","unstructured":"Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN et al (2018) Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. Elife.;7","DOI":"10.7554\/eLife.32271"},{"issue":"4","key":"5540_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.apsb.2018.05.010","volume":"8","author":"H Lyu","year":"2018","unstructured":"Lyu H, Han A, Polsdofer E, Liu S, Liu B (2018) Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B 8(4):503\u2013510","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"5540_CR56","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2217\/14796694.1.6.841","volume":"1","author":"TD Way","year":"2005","unstructured":"Way TD, Lin JK (2005) Role of HER2\/HER3 co-receptor in breast carcinogenesis. Future Oncol 1(6):841\u2013849","journal-title":"Future Oncol"},{"issue":"11","key":"5540_CR57","doi-asserted-by":"publisher","first-page":"9086","DOI":"10.18632\/oncotarget.3602","volume":"6","author":"M Shiota","year":"2015","unstructured":"Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E et al (2015) Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget 6(11):9086\u20139098","journal-title":"Oncotarget"},{"issue":"4","key":"5540_CR58","doi-asserted-by":"publisher","first-page":"e0297043","DOI":"10.1371\/journal.pone.0297043","volume":"19","author":"CE Fonseca-Alves","year":"2024","unstructured":"Fonseca-Alves CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, Amorim RL, Rogatto SR (2024) Lapatinib antitumor effect is associated with PI3K and MAPK pathway: an analysis in human and canine prostate cancer cells. PLoS ONE 19(4):e0297043","journal-title":"PLoS ONE"},{"issue":"1","key":"5540_CR59","doi-asserted-by":"publisher","first-page":"20263","DOI":"10.1038\/s41598-024-71181-0","volume":"14","author":"M Hu","year":"2024","unstructured":"Hu M, Liu R, Castro N, Loza Sanchez L, Rueankham L, Learn JA et al (2024) A novel lipophilic amiloride derivative efficiently kills chemoresistant breast cancer cells. Sci Rep 14(1):20263","journal-title":"Sci Rep"},{"key":"5540_CR60","doi-asserted-by":"crossref","unstructured":"Karlsson M, Zhang C, M\u00e9ar L, Zhong W, Digre A, Katona B et al (2021) A single-cell type transcriptomics map of human tissues. Sci Adv.;7(31)","DOI":"10.1126\/sciadv.abh2169"},{"issue":"8","key":"5540_CR61","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1074\/jbc.M115.686782","volume":"291","author":"R Reif","year":"2016","unstructured":"Reif R, Adawy A, Vartak N, Schr\u00f6der J, G\u00fcnther G, Ghallab A et al (2016) Activated ErbB3 translocates to the Nucleus via Clathrin-independent endocytosis, which is Associated with proliferating cells. J Biol Chem 291(8):3837\u20133847","journal-title":"J Biol Chem"},{"issue":"4","key":"5540_CR62","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1200\/JCO.2006.05.6853","volume":"25","author":"SF Shariat","year":"2007","unstructured":"Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM et al (2007) Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25(4):349\u2013355","journal-title":"J Clin Oncol"},{"issue":"2","key":"5540_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/(SICI)1097-0045(19990501)39:2<123::AID-PROS7>3.0.CO;2-2","volume":"39","author":"H Miyake","year":"1999","unstructured":"Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39(2):123\u2013129","journal-title":"Prostate"},{"issue":"9","key":"5540_CR64","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1096\/fj.02-0973com","volume":"17","author":"P PAKNESHAN","year":"2003","unstructured":"Pakneshan P, Xing RH, Rabbani SA (2003) Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 17(9):1081\u20131088","journal-title":"FASEB J"},{"issue":"9","key":"5540_CR65","first-page":"2372","volume":"54","author":"A Achbarou","year":"1994","unstructured":"Achbarou A, Kaiser S, Tremblay G, Ste-Marie L-G, Brodt P, Goltzman D et al (1994) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54(9):2372\u20132377","journal-title":"Cancer Res"},{"issue":"3","key":"5540_CR66","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0006-291X(05)80893-9","volume":"173","author":"SA Rabbani","year":"1990","unstructured":"Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J et al (1990) An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 173(3):1058\u20131064","journal-title":"Biochem Biophys Res Commun"},{"issue":"18","key":"5540_CR67","doi-asserted-by":"publisher","first-page":"8299","DOI":"10.1021\/acs.jmedchem.8b00838","volume":"61","author":"BJ Buckley","year":"2018","unstructured":"Buckley BJ, Aboelela A, Minaei E, Jiang LX, Xu Z, Ali U et al (2018) 6-Substituted hexamethylene amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer. J Med Chem 61(18):8299\u20138320","journal-title":"J Med Chem"},{"key":"5540_CR68","doi-asserted-by":"crossref","unstructured":"Hu M, Liu R, Lam KS, Carraway KL (2023) Structure-activity relationship study identifies a novel lipophilic amiloride derivative that induces lysosome-dependent cell death in therapy-resistant breast cancer cells. bioRxiv","DOI":"10.1101\/2023.05.25.542364"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05540-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05540-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05540-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T23:40:01Z","timestamp":1735256401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05540-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5540"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05540-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4844371\/v1","asserted-by":"object"}]},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"3 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to the contents of the publication. No other consent is necessary as all data presented have been generated by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest with the contents of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"24"}}